LC3-associated phagocytosis, a distinct form of autophagy, plays a key role in antigen presentation. Autophagy itself plays a central role in the regulation of cellular metabolism. Proteins that regulate autophagy include the AMPK which senses high levels of AMP, and mTOR, which integrates amino acid and fatty acid metabolism with autophagy. More recently, autophagy has been demonstrated to regulate tumor cell immunogenicity via the degradation of histone deacetylase proteins. Individual drugs and drug combinations that activate the ATM-AMPK pathway and inactivate mTOR, cause autophagosome formation. The maturation of autophagosomes into autolysosomes causes the autophagic degradation of histone deacetylase proteins who regulate the transcription of PD-L1, Class I MHCA, ODC and IDO1. Indeed, drug combinations that do not contain an HDAC inhibitor can nevertheless act as de facto HDAC inhibitors, via autophagic degradation of HDAC proteins. Such drug combinations simultaneously kill tumor cells via immunogenic autophagy and in parallel opsonize tumor cells to checkpoint inhibitor immunotherapies via reduced expression of PD-L1, ODC and IDO1, and increased expression of Class I MHCA.
INTRODUCTION
It is now well-recognized that LC3-associated phagocytosis (LAP), a specialized form of autophagy, causes the ingestion of non-self extracellular proteins whose breakdown product peptides are then used for antigen presentation on the cell surface [1] [2] [3] [4] [5] . The process is also essential for the efficient clearance of dead cells. However, this form of immune cell protein metabolism is not the only mechanism by which the anti-tumor effects of the immune system can be stimulated via autophagy. This review will discuss how autophagy, a cellular process evolved to maintain cellular homeostasis, also can indirectly regulate tumor cell immunogenicity (Figure 1 ).
Several years ago, we demonstrated that GI tumor cells were killed by the multi-kinase inhibitor sorafenib combined with the HDAC inhibitors vorinostat or sodium valproate, in part, via CD95 death receptor signalling and autophagosome formation; this data was translated into two clinical trials (NCT02349867; NCT01075113). Similar data in sarcoma cells using the multi-kinase inhibitor pazopanib combined with the novel HDAC inhibitor AR42 also resulted in a clinical trial (NCT02795819). Others have also demonstrated that autophagy is frequently a mechanism by which GI tumor cells can be killed by anti-cancer drugs, using the chemically dissimilar HDAC inhibitor panobinostat [6] [7] [8] .
HISTONE DEACETYLASE INHIBITORS AND HISTONE DEACETYLASE

PROTEINS
For two decades it has been understood that histone deacetylase proteins (HDACs) regulate chromatin condensation and the transcription of genes [9] [10] [11] [12] . Simplistically, by deacetylating histones associated with DNA, the inhibitors of HDACs should facilitate greater condensation and increased transcription. However, chemical inhibitors of HDACs were instead found to cause activation of some genes and for others to be inhibited. With the advent of checkpoint inhibitory immunotherapeutic antibodies, the possibilities of utilizing HDAC inhibitors to alter tumor cell immunogenicity via altered protein expression were clearly apparent [13] [14] [15] Immunometabolism   3 of 12   NCT03220477, NCT02697630, NCT03280563, NCT02559778, NCT02453620,   NCT03426891, NCT02400242, NCT04025931, NCT02805660, NCT03993626,   NCT02936752 ).
Figure 1. Autophagy regulates the expression of HDAC proteins which in turn leads to altered
transcription and enhanced tumor cell immunogenicity. HDAC inhibitors increase the acetylation of multiple protein chaperones, thereby reducing chaperone function. Reduced chaperone function increases the levels of denatured proteins, including growth factor receptors and signaling intermediates, leading to inactivation of the autophagy master regulator mTOR. In parallel, because of the abundance of denatured proteins and the reduced functionality of GRP78, an endoplasmic reticulum stress response from PERK to eIF2α to reduced protein translation occurs. Reduced GRP78 function also results in activation of the IRE1 ER stress pathway which via activation of the c-Jun NH2 terminal kinase pathway can also facilitate tumor cell death. Although translation from the majority of genes is reduced, some, such as the autophagy regulatory proteins Beclin1 and ATG5 is enhanced. With the inactivation of mTOR and increased levels of Beclin1 and ATG5, autophagosome formation is enhanced. Encapsulated HDAC proteins in the autophagosome, following fusion with acidic endosomes to become autolysosomes, are degraded. Reduced expression of HDACs alters the transcription of many genes, notably that the protein levels of PD-L1, ODC Nota bene: degradation of ERBB1 required ubiquitination and autophagy whereas degradation of c-MET was independent of ubiquitination. We went on to determine that the combination of neratinib and HDAC inhibitors reduced the expression of plasma membrane localized mutant RAS proteins, and that this process of receptor/RAS internalization and degradation was dependent upon the protein Rubicon, i.e., LC3-associated phagocytosis was required for plasma membrane protein degradation effects [16, [18] [19] [20] [21] . These findings also have implications for the immune cells themselves. Neratinib, via inhibition of the MAP4Ks MST2/MST3/MST4, was shown to down-regulate RAS proteins not only in carcinoma cells but also in blood cancer cells [21] .
In parallel to this project, another series of studies was defining the molecular mechanisms by which the thymidylate synthase and lung cancer therapeutic pemetrexed interacted with the phosphodiesterase 5
inhibitor sildenafil (Viagra) to kill non-small cell lung cancer cells. Because of the efficacy of checkpoint inhibitory immunotherapy antibodies in this disease, we also determined whether our drug combination had the potential to opsonize tumor cells to the novel immunotherapy [22, 23] .
With both [neratinib + HDAC inhibitors] and [pemetrexed + sildenafil], as
well as with other regimens which strongly induced autophagosome formation, we observed that drug-treated cells rapidly reduced their expression of PD-L1, ODC and IDO-1, and increased their expression of Class I MHCA [24, 25] . Our initial rationalization of these findings was that altered cell signaling processes, including transcription factors, likely played a key role in altered protein expression. However, in the case of cells exposed to pemetrexed and sildenafil, we observed that drug-induced activation of ataxia telangiectasia (ATM) regulated autophagosome formation via the AMP-dependent protein kinase (AMPK) and simultaneously also caused the inactivation of the ATPase activity of the chaperone HSP90. Inactivation of the HSP90 ATPase was associated with increased acetylation of the chaperone and decreased expression of the HDAC which deacetylates HSP90, HDAC6 [26, 27] . HDAC6 and HSP90 were degraded via autophagosome formation. Reduced HSP90 function was shown to enhance the levels of denatured proteins, which in the endoplasmic reticulum, is sensed by the chaperone GRP78 and PKR-like endoplasmic reticulum kinase (PERK) [28, 29] . GRP78 dissociates from PERK to chaperone and renature the denatured proteins, causing PERK to become activated and to phosphorylate eIF2α; phosphorylation of eIF2 α results in the translation of most mRNA molecules to decline, though for Immunometabolism. 2020;2(1):e200002. https://doi.org/10.20900/immunometab20200002 Immunometabolism 5 of 12 some genes such as the autophagosome-regulatory ATG5 and Beclin1, the reverse is true [30, 31] .
HDAC6 was being degraded by autophagy and in our extensive screening studies examining signal transduction pathways, no obvious association could be made between the rapid drug-effects on the pathways or transcription factors and the rapid alterations in the expression of PD-L1, MHCA, ODC or IDO1 [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . Hence, we determined whether the pemetrexed and sildenafil combination or the neratinib and HDAC inhibitor combination altered the protein expression of individual HDAC proteins (HDACs1-11). Over a series of research manuscripts, we discovered that multiple HDAC proteins were susceptible to degradation via drug-induced autophagy, e.g., [17, [23] [24] [25] . HDACs1-3 and HDAC6 were consistently demonstrated, between cell types and different drug combinations, to have their expression reduced via autophagosome formation [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] .
It is well-known that HDAC inhibitors can influence the biology of the immune cells outside and within a tumor [14, [32] [33] [34] . In general, HDAC inhibitors are viewed as acting in a positive fashion, increasing the activity of immune cells, including T cells and macrophages [35, 36] . 
IN VIVO ASSESSMENTS OF TUMOR CELL IMMUNOGENICITY AFTER
EXPOSURE TO DRUG COMBINATIONS WHICH PROMOTE
AUTOPHAGOSOME FORMATION
Our in vitro data experiences with a diverse cohort of different drug combinations that all rapidly induce autophagosome formation, endoplasmic reticulum stress signalling and HDAC metabolism would all a priori predict for enhanced tumor cell immunogenicity in pre-clinical mouse models. Below we discuss some of our findings.
LEWIS LUNG CARCINOMA TUMOURS
In Lewis Lung Carcinoma tumours [22, 23] 
B16 MELANOMA TUMORS
In B16 melanoma tumors [25] ; the HDAC inhibitors AR42 or sodium valproate enhanced the efficacy of both anti-PD1 or anti-CTLA4 antibodies.
Prior [pazopanib + HDAC inhibitor] exposure caused higher levels of the combination re-programs the surviving tumor cells in vivo to express less of these HDACs in tumors over a longer time period (weeks).
4T1 MAMMARY CARCINOMA TUMORS
PAN02 PANCREATIC TUMORS
In PAN02 pancreatic tumors [24] ; prior exposure of the tumours to the multi-kinase inhibitor sorafenib and the HDAC inhibitor vorinostat enhanced the efficacy of an anti-PD1 antibody. Twenty days after the end of any sorafenib/vorinostat/antibody exposure the levels of K-RAS in the tumor cells remained significantly reduced, as was ERBB1expression. The level of IDO-1 was significantly lower in tumors exposed previously to p70 were increased in the drug exposed tumors. In the plasma, the amount of CXCL-13, CXCL-5, IL-16, CCL7, CXCL-16 and CXCL-12 were increased. No significant reductions in the levels of any plasma cytokine were observed.
CONCLUSIONS
In multiple manuscripts we have demonstrated that drugs and 
